The metabolic syndrome in type 1 diabetes: does it exist and does it matter?

The significance of the metabolic syndrome in type 1 diabetes is not well understood. This study aimed to estimate its prevalence and attendant complications. Four hundred twenty-seven type 1 diabetic subjects were grouped according to the presence or absence of metabolic syndrome (WHO criteria). Macro- and microvascular complications were compared between the groups as individual and as composite endpoints. Data were analyzed for the total cohort and in subgroups according to duration of diabetes quartiles (<6.9, 7-12.9, 13-19.9, and >20 years) and year of presentation. Fifteen percent of individuals fulfilled the WHO criteria for metabolic syndrome, and of these, 26.9% were insulin resistant, as compared with 3.4% of those without metabolic syndrome [odds ratio (OR)=8.9, P=.001]. Both BMI and metabolic syndrome showed an increasing trend from 1992 to 2003. Those with metabolic syndrome required significantly higher insulin dosage [0.9 (0.7-1.2) vs. 0.6 (0.5-0.9) units/kg, P=.03], were older [35.0 (26.2-47.3) vs. 29.7 (23.4-36.4) years, P=.002], and had longer duration of diabetes [19.7 (10.7-25.6) vs. 12.1 (6.3-17.9) years, P=.0001]. They also had a significantly higher macrovascular composite endpoint (OR=3.3, P=.02) as well as higher macrovascular and microvascular composite endpoint (OR=3.1, P=.0001). The prevalence of stroke (OR=22.8, P=.008), peripheral vascular disease (OR=7.3, P=.05), and severe retinopathy (OR=3.7, P=.01) is higher in subjects with metabolic syndrome in the >or=20-year quartile group; in addition, these subjects have higher macrovascular composite endpoint (OR=3.9, P=.03) and macrovascular and microvascular composite endpoint (OR=2.9, P=.03). This remained so even when subjects with albuminuria were excluded. Some individuals with type 1 diabetes can also have metabolic syndrome. They are more prone to complications and require even more intensive glycemic control and reduction of macrovascular risk factors.

[1]  E. Gale.  The myth of the metabolic syndrome , 2005, Diabetologia.

[2]  J. Hamilton,et al.  Potential Adjunctive Therapies in Adolescents with Type 1 Diabetes Mellitus , 2004, Treatments in endocrinology.

[3]  P. Zimmet,et al.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[4]  T. Orchard,et al.  Can clinical factors estimate insulin resistance in type 1 diabetes? , 2000, Diabetes.

[5]  L. Gaal,et al.  Impact of Overweight on Chronic Microvascular Complications in Type 1 Diabetic Patients , 2005 .

[6]  A. Biggeri,et al.  Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. , 2004, Diabetes care.

[7]  E. Bonora,et al.  The Metabolic Syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study , 2004, Diabetic medicine : a journal of the British Diabetic Association.

[8]  Ken Williams,et al.  Identification of individuals with insulin resistance using routine clinical measurements. , 2005, Diabetes.

[9]  E. Lakatta,et al.  The metabolic syndrome in older individuals: prevalence and prediction of cardiovascular events: the Cardiovascular Health Study. , 2005, Diabetes care.

[10]  R. LaPorte,et al.  Changing prevalence of overweight children and adolescents at onset of insulin-treated diabetes. , 2003, Diabetes care.

[11]  L. Groop,et al.  The metabolic syndrome influences the risk of chronic complications in patients with Type II diabetes , 2001, Diabetologia.

[12]  D. Finegood,et al.  Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: a randomized controlled trial. , 2003, Diabetes care.

[13]  G. W. Snedecor.  Statistical Methods , 1964 .

[14]  Merlin C. Thomas,et al.  Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). , 2005, Diabetes care.

[15]  T. Orchard,et al.  Improved glycemic control reduces the impact of weight gain on cardiovascular risk factors in type 1 diabetes. The Epidemiology of Diabetes Complications Study. , 1999, Diabetes care.

[16]  P. Lehert,et al.  The benefits of metformin therapy during continuous subcutaneous insulin infusion treatment of type 1 diabetic patients. , 2002, Diabetes care.

[17]  R. Klein,et al.  The epidemiology of diabetes complications study. IV. Correlates of diabetic background and proliferative retinopathy. , 1991, American journal of epidemiology.

[18]  L. Groop,et al.  Cardiovascular morbidity and mortality associated with the metabolic syndrome. , 2001, Diabetes care.

[19]  S. Teutsch,et al.  THIRD NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY (NHANES III); NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP). NCEP-DEFI NED METABOLIC SYNDROME, DIABETES, AND PREVALENCE OF CORONARY HEART DISEASE AMONG NHANES III PARTICIPANTS AGE 50 YEARS AND OLDER , 2003 .

[20]  Richard Kahn,et al.  The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. , 2005, Diabetes care.

[21]  S. Teutsch,et al.  NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. , 2003, Diabetes.